About Us

Part of an established International Group Siinovia is headquartered in London and focused on delivering niche generic and value-added medicines to the UK and EU healthcare markets.

Our expertise spans the full product lifecycle; licensing, development, manufacturing, and distribution – providing our partners with a single, reliable point at each stage.

About the SIINOVIA company

Our Approach

Delivering complex generics with confidence

http://Innovation%20at%20the%20core

Innovation at the Core

Innovation is central to our philosophy and drives our approach. We continuously refine formulations, optimise delivery systems, and streamline supply strategies to ensure high-quality medicines reach patients with specific and underserved therapeutic needs efficiently, safely, and reliably.

http://Quality,%20and%20Regulatory%20Excellence

Quality, and Regulatory Excellence

Our long-standing success over a decade is built on trusted relationships with manufacturing partners, regulatory authorities, and healthcare stakeholders. Through transparent collaboration and a strong network of approved manufacturing facilities across Europe and beyond, we uphold the highest levels of regulatory compliance, product quality, and supply reliability.

Strategy

  • Focus: Niche chronic therapeutic
  • Competitor differentiation: Technically complex products (both chemically and clinically)
  • Speed to market from molecule identification, development, licensing and commercialisation
  • Further development of existing molecules to fulfil unmet clinical needs

Balancing Current profitability for future growth investments

  • Acquisitions of further mature products from multinational pharma companies.
  • Capital intensive development of further complex generic molecules
http://Strategy,%20Growth,%20Balancing

Growth

  • Geographical spread with our existing product portfolio: MRP procedures to other EU states. License applications to the US, Australia and Canada.
  • Further product launches from our internal product pipeline, which currently consists of over 40 molecules.
  • Line extensions and new dosage forms of existing products to cater for unmet clinical needs. Optimisation of operational costs.
Specialities

The company specialises in the development and registration of high value, technically demanding formulations and also pursues first file opportunities.

Capabilities

Access to both in-house and external regulatory, development and manufacturing capabilities in Europe and Asia.

Future Focus

Over 40 pharmaceutical products in various stages of development and registration.